Indication Type | Indication |
Used in combination to treat | Advanced hr + her2 - breast cancer |
Used as adjunct in combination to treat | Early hormone receptor positive, her2/neu negative node positive breast cancer |
Used in combination to treat | Metastatic hr + her2 - breast cancer |
People also ask
What is the approved indication for abemaciclib?
What is abemaciclib used to treat?
Who is eligible for abemaciclib?
What are the indications for Verzenio?
Mar 3, 2023 ˇ The Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor)
VERZENIO (abemaciclib) is indicated: • in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, ...
Mar 3, 2023 ˇ "Our goal in intensifying treatment for early breast cancer is to maintain remission and prevent the recurrence of cancer. The magnitude of ...
Mar 16, 2023 ˇ Latest approval removes the Ki-67 testing requirement. Full prescribing information for Verzenio is available here.
Early Breast Cancer. Indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of hormone receptor ...
Apr 10, 2023 ˇ Abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)- ...
Verzenio (abemaciclib) is a treatment for both HR+, HER2-, high risk, node positive early breast cancer and for certain types of HR+, HER2- metastatic ...
Indication: In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth ...
Missing: Indications | Show results with:Indications
Apr 3, 2023 ˇ Abemaciclib (Verzenio – Lilly) has been approved by the FDA for use in combination with endocrine therapy (tamoxifen or an aromatase inhibitor)
Missing: Indications | Show results with:Indications
